HUMA DEADLINE: ROSEN, A HIGHLY REGARDED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Class Action Lawsuit Details - A class action lawsuit has been filed against Humacyte, Inc (NASDAQ: HUMA) for purchasers of securities between May 10, 2024, and October 17, 2024 [4] - The lawsuit alleges that Humacyte made false and/or misleading statements and/or failed to disclose critical information regarding its Durham, North Carolina facility's non-compliance with good manufacturing practices, including quality assurance and microbial testing [7] - The lawsuit claims that the FDA's review of Humacyte's Biologics License Application (BLA) was delayed due to the need for remediation of these deficiencies, posing a substantial risk to FDA approval of Acellular Tissue Engineered Vessel (ATEV) for vascular trauma [7] - Investors allegedly suffered damages when the true details entered the market, as the defendants' positive statements about Humacyte's business, operations, and prospects were materially misleading and/or lacked a reasonable basis [7] Legal Representation and Deadlines - The Rosen Law Firm is reminding purchasers of Humacyte securities during the Class Period of the important January 17, 2025, lead plaintiff deadline [4] - Investors who purchased Humacyte securities during the Class Period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement [4] - The Rosen Law Firm encourages investors to select qualified counsel with a track record of success in leadership roles, emphasizing its own achievements, including securing over $438 million for investors in 2019 and being ranked No 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017 [5] Participation in the Class Action - Investors can join the Humacyte class action by visiting the Rosen Law Firm's website or contacting Phillip Kim, Esq toll-free at 866-767-3653 or via email at case@rosenlegal com [2][6] - No class has been certified yet, and until a class is certified, investors are not represented by counsel unless they retain one Investors may select counsel of their choice or remain an absent class member [8]